comparemela.com

Latest Breaking News On - System atrophy national institute of neurological disorders - Page 1 : comparemela.com

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today.

United statesSan franciscoHannah howlettRemy bernardaMargaret bradburyDanielo claassenDavid stamlerDaniel claassenVanderbilt university medical centerSecurities exchangeParkinson foundationEuropean commissionSystem atrophy national institute of neurological disordersNonclinical developmentDepartment of pharmaceutical sciencesWorld orphan drug congress united states

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201.

United statesSan franciscoDavid stamlerMargaret bradburyDanielo claassenDaniel claassenRemy bernardaHannah howlettParkinson foundationEuropean commissionNonclinical developmentSecurities exchangeSystem atrophy national institute of neurological disordersVanderbilt university medical centerInternational conferenceAlterity therapeutics

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 Alterity Therapeutics , a.

United statesSan franciscoHannah howlettRemy bernardaDavid stamlerDrug administrationData monitoring committeeSecurities exchangeSystem atrophy national institute of neurological disordersAlterity therapeuticsEuropean commissionLine data expectedChief executive officerMultiple system atrophySystem atrophyNational institute

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today.

United statesSan franciscoDaniel claassenHannah howlettPaula trujillo diazDavid stamlerRemy bernardaEuropean commissionCompany biomarkersVanderbilt university medical centerDepartment of neurologyResearch assistant professorSystem atrophy national institute of neurological disordersAlterity therapeuticsSecurities exchangeInternational symposium

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants globally – MELBOURNE, Australia.

New zealandUnited statesSan franciscoDavid stamlerRemy bernardaHannah howlettAlterity therapeuticsEuropean commissionSecurities exchangeSystem atrophy national institute of neurological disordersChief executive officerMultiple system atrophySystem atrophyNational instituteNeurological disordersMultiple system

vimarsana © 2020. All Rights Reserved.